- Home
- AUUD vs THAR Comparison
AUUD vs THAR Comparison
Compare AUUD & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- THAR
- Stock Information
- Founded
- AUUD 2012
- THAR 2017
- Country
- AUUD United States
- THAR United States
- Employees
- AUUD N/A
- THAR N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- THAR Health Care
- Exchange
- AUUD Nasdaq
- THAR Nasdaq
- Market Cap
- AUUD 3.1M
- THAR 2.8M
- IPO Year
- AUUD 2021
- THAR 2022
- Fundamental
- Price
- AUUD $0.50
- THAR $2.10
- Analyst Decision
- AUUD
- THAR
- Analyst Count
- AUUD 0
- THAR 0
- Target Price
- AUUD N/A
- THAR N/A
- AVG Volume (30 Days)
- AUUD 97.2K
- THAR 222.9K
- Earning Date
- AUUD 11-07-2024
- THAR 11-07-2024
- Dividend Yield
- AUUD N/A
- THAR N/A
- EPS Growth
- AUUD N/A
- THAR N/A
- EPS
- AUUD N/A
- THAR N/A
- Revenue
- AUUD N/A
- THAR N/A
- Revenue This Year
- AUUD N/A
- THAR N/A
- Revenue Next Year
- AUUD N/A
- THAR N/A
- P/E Ratio
- AUUD N/A
- THAR N/A
- Revenue Growth
- AUUD N/A
- THAR N/A
- 52 Week Low
- AUUD $0.48
- THAR $1.84
- 52 Week High
- AUUD $11.75
- THAR $8.42
- Technical
- Relative Strength Index (RSI)
- AUUD 36.30
- THAR 43.79
- Support Level
- AUUD $0.58
- THAR $2.09
- Resistance Level
- AUUD $0.57
- THAR $2.27
- Average True Range (ATR)
- AUUD 0.05
- THAR 0.18
- MACD
- AUUD -0.01
- THAR -0.01
- Stochastic Oscillator
- AUUD 1.18
- THAR 17.02
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.